A Synthetic Cannabinoid Eye Drop Lowered Eye Pressure in Treatment-Resistant Glaucoma
A synthetic cannabinoid (WIN 55212-2) applied as eye drops reduced intraocular pressure by up to 31% in glaucoma patients who had not responded to conventional treatments.
Quick Facts
What This Study Found
The synthetic CB1 receptor agonist WIN 55212-2, applied topically to the eye, reduced intraocular pressure in 8 patients with glaucoma resistant to conventional therapies. At the 25-microgram dose, pressure decreased by 15% within 30 minutes and reached a maximum reduction of 20% at 60 minutes. At the 50-microgram dose, pressure decreased by 23% within 30 minutes and reached a maximum reduction of 31% at 60 minutes.
The researchers had previously demonstrated the presence of CB1 receptor mRNA and protein in the human ciliary body, establishing a biological mechanism for the pressure-lowering effect. These results confirmed that CB1 receptors directly regulate human intraocular pressure.
Key Numbers
Eight patients were treated. At 25 micrograms: 15% pressure reduction at 30 minutes, 20% maximum at 60 minutes. At 50 micrograms: 23% reduction at 30 minutes, 31% maximum at 60 minutes.
How They Did This
This was a small clinical study in which 8 patients with glaucoma resistant to conventional therapies received topical application of the synthetic CB1 agonist WIN 55212-2 at doses of 25 or 50 micrograms. Intraocular pressure was measured at 30-minute and 60-minute intervals after application.
Why This Research Matters
While cannabis has long been known to lower eye pressure, its use for glaucoma has been limited by short duration of effect and systemic side effects. This study demonstrated that a topical synthetic cannabinoid could achieve meaningful pressure reduction directly in the eye, potentially avoiding systemic effects. The fact that it worked in treatment-resistant patients made it particularly significant.
The Bigger Picture
Despite these promising results, cannabinoid-based eye drops have not become a standard glaucoma treatment. The short duration of effect remains a challenge, as glaucoma requires 24-hour pressure control. However, this study established proof of concept for topical cannabinoid delivery to the eye and confirmed the role of CB1 receptors in regulating intraocular pressure.
What This Study Doesn't Tell Us
The study included only 8 patients with no placebo control group. Duration of the pressure-lowering effect beyond 60 minutes was not reported. Long-term safety and efficacy of repeated dosing were not assessed. The study did not compare results with existing topical glaucoma medications.
Questions This Raises
- ?How long did the pressure-lowering effect last beyond the 60-minute measurement?
- ?Could sustained-release formulations extend the duration of effect enough for practical glaucoma management?
- ?Why have topical cannabinoid eye drops not progressed further in clinical development?
Trust & Context
- Key Stat:
- 31% maximum pressure reduction at 50-microgram dose
- Evidence Grade:
- This is a small pilot study with 8 patients and no placebo control, providing preliminary evidence of concept.
- Study Age:
- Published in 2001. Despite these results, cannabinoid eye drops have not become a standard glaucoma treatment.
- Original Title:
- The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies.
- Published In:
- The European journal of neuroscience, 13(2), 409-12 (2001)
- Authors:
- Porcella, A(2), Maxia, C, Gessa, G L(3), Pani, L
- Database ID:
- RTHC-00112
Evidence Hierarchy
A small preliminary study to test whether a larger study is feasible.
What do these levels mean? →Frequently Asked Questions
Can cannabis treat glaucoma?
Cannabis can lower eye pressure, but the effect is short-lived (about an hour in this study). Glaucoma requires constant 24-hour pressure management, making cannabis impractical as a standalone treatment with current formulations.
What makes this different from smoking cannabis for glaucoma?
This study used a targeted eye drop rather than systemic cannabis, which could avoid the psychoactive effects and other side effects of smoking. The eye drop delivered the cannabinoid directly to where it was needed.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00112APA
Porcella, A; Maxia, C; Gessa, G L; Pani, L. (2001). The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies.. The European journal of neuroscience, 13(2), 409-12.
MLA
Porcella, A, et al. "The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies.." The European journal of neuroscience, 2001.
RethinkTHC
RethinkTHC Research Database. "The synthetic cannabinoid WIN55212-2 decreases the intraocul..." RTHC-00112. Retrieved from https://rethinkthc.com/research/porcella-2001-the-synthetic-cannabinoid-win552122
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.